Life sciences provider TAKE Solutions on Thursday recorded consolidated net profit at ₹27.06 crore for the fourth quarter ending March 2019, compared to ₹45.49 crore registered year ago.
For the year ending March 31, 2019, the city-headquartered firm’s net profit went upto ₹178.39 crore from ₹159.86 crore recorded year ago.
Total revenue for the January-March 2019 quarter went upto ₹535.88 crore from ₹456.79 crore.
For fiscal 2018-19, total revenue surged to ₹2,049.74 crore against ₹1,593.65 crore registered year ago.
The company also announced the acquisition of KAI Research, full service health research company.
“Through this acquisition, TAKE builds Phase II and Phase III capabilities in North America adding to its current service offerings in Europe and Asia,” a company release said.
On the financial performance, company Vice-Chairman and Managing Director (HR), Srinivasan said TAKE recorded a positive growth rate this year to 28.5 per cent with continued strong performance in the life sciences business.
“We will continue to invest ahead of the growth curve to position us as the most preferred business partner for global pharmaceuticals,” he said.
“Through this acquisition, we also gain a unique standpoint in serving agencies like FDA, NIMH, Department of Defence..,” he said.
The Board of Directors has recommended a final dividend of 40 per cent (Rs 0.40 per equity share of value Rs one each), subject to the approval of shareholders.